Floatz logo

Bmn 701

Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset

BioMarin PharmaceuticalPhase 3Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Glycogen Storage Disease Due To Acid Maltase Deficiency, Late-Onset cohort.

Asset / SponsorPhaseRating
Alglucosidase Alfa
Erasmus Medical Center
Phase 4BBB
Cipaglucosidase Alfa-ATGA
Amicus Therapeutics
Phase 3BB
Avalglucosidase Alfa
Iris Plug
Phase 4BB
at2221
Amicus Therapeutics
Phase 3B
Miglustat
Amicus Therapeutics
Phase 3B

View all 13 →

Same molecule, other indications

Bmn 701 is also rated in:

glycogen storage disease IIDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →